These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples.
    Author: Tsui KH, Juang HH, Lee TH, Chang PL, Chen CL, Yung BY.
    Journal: Acta Pharmacol Sin; 2008 Mar; 29(3):364-70. PubMed ID: 18298902.
    Abstract:
    AIM: To investigate the possible correlation of nucleophosmin/B23 expression with bladder carcinoma recurrence. METHODS: Surgically-resected bladder tumors staged pTa to pT4 were examined for nucleophosmin/B23 expression by immuno-histochemistry. The study group consisted of 132 consecutive patients surgically treated at Chang Gung Memorial Hospital between December 1998 and November 1999. The mean follow up was 72 months (range: 48-84 months). RESULTS: Nuclear nucleophosmin/B23 staining was detected in 96% of advanced stage and poorly-differentiated tumors. Higher nucleophosmin/B23 levels were linked to more advanced tumor stages, grades, poor prognosis, and likelihood of recurrence (P<0.05). The Cox multivariate analysis indicated the nucleophosmin/B23 expression as an independent indicator for tumor recurrence (P=0.009). CONCLUSION: The results suggest that nucleophosmin/B23 is a favorable prognostic indicator for bladder cancer. Nucleophosmin/B23 could be a useful molecular tumor marker for predicting bladder cancer recurrence.
    [Abstract] [Full Text] [Related] [New Search]